Drug Profile
Bevacizumab biosimilar - Prestige Biopharma
Alternative Names: HD 204Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Hanwha Biologics
- Developer Prestige BioPharma
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Non-small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 27 Jul 2022 Bevacizumab biosimilar licensed marketing rights to Intas Pharmaceutical in Brazil, Canada, Europe, Indonesia, Kyrgyzstan, Malaysia, Mexico, Philippines, Singapore, South Africa, Tajikistan, Thailand, USA, Vietnam and MENA countries
- 21 Feb 2022 Prestige BioPharma plans regulatory filings with EMA and US FDA in 2023
- 28 Jul 2021 No recent reports of development identified for phase-I development in Solid-tumours(In volunteers) in New Zealand (IV, Infusion)